Pfizer Inversion: Prickly Politics For Pharma
This article was originally published in Scrip
Executive Summary
Certainly, Pfizer Inc. knew what it was doing when it decided to consider another possible merger under a tax inversion scheme in the midst of the high-stakes political battle ongoing in the US – bringing with such a move more condemnation of the entire biopharmaceutical industry, which already is under fire for certain firms' drug pricing practices and some shady looking relationships with specialty pharmacies.